Abstract. The present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC). Mouse models of human cSCC were constructed by injecting human cutaneous squamous cell carcinoma cells into both flanks of nude mice. Subsequently, the 75 nude mice with cSCC xenograft tumors were randomly divided into recombinant human serotype 5 adenovirus (rAd)/p53, rAd/p53 + 5-fluorouracil (5-Fu) and 5-Fu groups. One side of the tumors was administered the therapeutic agents as the therapeutic group, whereas the remaining side was treated with medical saline as the control. At 24, 48, 72, 120 and 168 h post-intratumoral injection, alterations in tumor volume, tumor necrosis and the expression of several tumor-associated genes, including Smad4, Brca1 and matrix metalloproteinase (MMP-2), were analyzed. Compared with its control group, the rAd/P53 group exhibited a significantly increased tumor necrosis ratio. In addition, Smad4 and Brca1 expression levels increased significantly at various time points (P<0.05), and MMP-2 expression decreased significantly (P<0.05). In the rAd/p53 + 5-Fu group, the tumor necrosis ratio, and Smad4 and Brca1 expression levels also significantly increased at various time points (P<0.05). MMP-2 gene transcription gradually decreased, high expression of Smad4 was prolonged, and high expression of Brca1 was observed in the early period following treatment compared with the rAd/P53 group. In addition, p53 expression exhibited a positive correlation with the tumor necrosis ratio and Smad4 expression, and showed a negative correlation with MMP-2 gene transcription (P<0.05). These findings indicate that rAd/p53 has a potent anti-tumor effect in cSCC via the promotion of tumor necrosis and regulating the expression of various tumor-associated genes.
Introduction
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent malignancy, particularly in fair-skinned individuals, second only to cutaneous basal cell carcinoma (1) . Surgical excision remains the gold standard therapy for the majority of patients with cSCC since it allows adequate treatment for tumors via histological examination of the margins of the excised tissues (2) . However, in many patients, these lesions may metastasize to new body sites, leading to poor prognosis (3) . For metastatic cSCC, curative treatment is no longer available, and the effectiveness of chemotherapy or the treatment with reported biologic-response modifiers remains unknown (4); therefore it is crucial that novel treatment strategies against cSCC are explored.
Cumulative exposure to ultraviolet B radiation from sunlight is a major cause of cSCC (5) . Ultraviolet radiation is able to generate specific mutations in DNA via the formation of thymidine dimers in the p53 tumor-suppressor gene. If these mutations are not successfully repaired, keratinocytes with dysfunctional p53 do not undergo apoptosis and instead undergo clonal expansion, leading to the formation of cSCC (6) . Hence, the reconstitution of a wild-type p53 (wt-p53) gene is a promising anticancer therapy against cSCC. Gendicine, a recombinant human serotype 5 adenovirus (rAd/p53) in which the E1 region has been replaced by a human wt-p53 expression cassette, is the first commercial gene therapy product against multiple cancer (7) . The therapeutic p53 gene in Gendicine can be delivered into the cytoplasm and the cell nucleus of the tumor target cells via an adenoviral particle infecting the tumor cells. Subsequently, the wt-p53 gene undergoes transcription and translation in tumor target cells (8) . The expressed p53 genes exhibit their antitumor effects by promoting the apoptosis of tumor target cells, inhibiting the transcription of survival signals in tumor cells and activating the immune response in host cells (8) . Gendicine was first reported as a treatment for head and neck cancers and was later discovered to have antitumor effects against several other malignancies (9-12). However, few studies have been performed to explore the antitumor effects of Gendicine on cSCC.
Smad4, which is a potent tumor suppressor in various malignant neoplasms, has been reported to exhibit two anti-tumor effects in pancreatic cancer vs. head-neck cancer (13) . Furthermore, downregulation of Smad4 has been demonstrated in a human cSCC cell line (A431) (14) . Abnormal expression of Brca1, which is a breast cancer susceptibility gene that encodes a nuclear phosphoprotein, has been shown to be associated with the treatment failure of advanced squamous cervical cancer (15, 16) . Matrix metalloproteinase 2 (MMP-2), a zinc-dependent endopeptidase, has a prominent role in the invasive ability of tumor cells, and it has previously been reported that MMP-2 levels may be reduced by the wt-p53 gene in p53-mutated human melanoma cells (17) .
Therefore, the present study was conducted to identify the antitumor effects of Gendicine (rAd/p53) on cSCC in a mouse model via the following: i) Calculation of tumor volume; ii) assessment of tumor necrosis; iii) detection of the expression of antitumor genes, including Smad 4 and Brcal, and the pro-oncogenes of MMP-2; iv) analysis of the correlation between the expression of p53 and the above findings. In addition, the anti-tumor effects of rAd/p53 were compared with that of 5-fluorouracil (5-Fu) and the combined therapy of rAd/p53 with 5-Fu.
Materials and methods
Cell lines. A431 human cutaneous squamous cell carcinoma cell line was purchased from the Cell Bank of the Chinese Academy of Science (Wuhan, China). Cells were maintained in Dulbecco's modified Eagle medium (DMEM)/F-12 supplemented with 3% fetal bovine serum, 80 U/ml penicillin and 80 mg/ml streptomycin (all Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were cultured in a humidified incubator at 37˚C with 5% CO 2 for 3-4 days until the cells completely covered the bottom of the flask. Subsequently, cells were enzymatically detached via treatment with 0.25% trypsin-EDTA for 5 min, and viable cell counting was performed with trypan blue exclusion. Finally, cells were resuspended in Dulbecco's phosphate-buffered saline at 1x10 7 cells/ml for subcutaneous inoculation.
Animals.
A total of 75 BALB/c female nude mice, 6-weeks-old and weighing 19-25 g, were obtained from the animal center of Daping Hospital, Research Institute of Surgery, Third Military Medical University (Chongqing, China) and bred under pathogen-free conditions. Animals were housed under a 12-h light/dark cycle at 22-23˚C with free access to food and water. The present animal study was approved by the Animal Use and Care Committee of Xinqiao Hospital (Chongqing, China).
All animal experiments were performed in accordance with institutional guidelines. All efforts were made to minimize the animal suffering and to limit the number of mice used.
Animal tumor model and treatment groups. Mice (n=75) were subcutaneously injected with 0.5x10 7 A431 cells in both flanks to generate xenograft models. Ten days after injection, mice were randomized into three equal groups: rAd/p53 (Gendicine; Sibiono GeneTech Co., Ltd., Shenzhen, China) group (n=25), 5-Fu group (n=25) and rAd/p53 + 5-Fu group (n=25). Tumors on one side were intratumorally injected with the respective therapeutic agents (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Injection frequency was once a week for rAd/P53, and once every three days for 5-Fu according to the manufacturer's instructions. Tumors on the remaining side were intratumorally injected with medical saline once time and were indicated as the respective control groups. In accordance with the preparation method for gendicine, the rAd/P53 power was dissolved in medical saline and the concentration of rAd/P53 solution was 5x10 11 virus particles/ml. Injection dosage was set to 0.1 ml for tumors with the largest diameters of 0.2-0.4 cm, 0.2 ml for 0.5-0.7 cm tumors, and 0.4 ml for 0.8-1.0 cm tumors. Dosage of 5-Fu (250 mg:10 ml) was set to 2.5 mg:0.1 ml for 0.2-0.4 cm tumors, 5 mg:0.2 ml for 0.5-0.7 cm tumor, and 10 mg:0.4 ml for 0.8-1.0 cm tumors.
Calculation of tumor volume. At each time point (24, 48, 72 , 120 and 168 h after intratumoral injection), five mice from each group were randomly selected, and were sacrificed via an overdose of anesthetic (ketamine, 200 mg/kg, i.p.; Sigma-Aldrich). The length and width of the excised tumors were measured. Tumor volume was calculated as tumor volume = length x width 2 . Subsequently, tumors from both flanks of each mouse were divided into equal halves. One part was immediately frozen at -80˚C for western blot and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, and the other was immersed in 4% formaldehyde solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE) to assess the necrosis of the tumors.
Assessment of tumor necrosis. Pathologic sections stained with HE were evaluated by two pathologists for tumor necrosis analysis. The tumor necrosis ratio was calculated as the ratio of the necrotic area on the HE section at x100 magnification. The relative tumor necrosis ratio (rTNR) was calculated as the TNR of the therapeutic groups at each time point divided by the TNR of the corresponding control group. The mean of the evaluations by the pathologists was used for analysis.
Western blot analysis. Expression levels of adenovirus-carried wt-p53, Smad4 and Brca1 in the tumors following different treatments were detected by western blotting. Briefly, tumor tissues were first homogenized with lysis buffer on ice. Then lysates from tissues samples were isolated by centrifugation at 2,500 x g and 4˚C for 30 min. Total tumor protein from all tissue samples were quantified using a standard bicinchoninic acid assay (Pierce Protein Biology; Thermo Fisher Scientific, Inc., Rockford, IL, USA). After quantification, total proteins (20 µg) were separated using 10% SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. Then membranes were incubated in 5% milk in 0.1% Tris-buffered saline-Tween 20 (TBST) at room temperature for 2 h. After washed with TBST for three times at room temperature, membranes were incubated with rabbit anti-mouse primary antibodies P53 (1:100; sc-6243), Smad4 (1:100; sc-7154), Brca-1 (1:200; sc-7869) and GAPDH (1:200; sc-367714; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4˚C overnight. The next day, membranes were incubated with infrared-labeled secondary antibodies (donkey anti-rabbit IRDye 800; 1:500; P/N 925-32213; LI-COR Biosciences, Lincoln, NE, USA) at room temperature for 1 h at room temperature after washed with TBST. Band intensities were scanned into the computer and analyzed with Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). The relative integral optical density (rIOD) of protein expression was calculated as the IOD of the protein in the control groups and therapeutic groups at each time point divided by the corresponding IOD of GAPDH. IOD ratio of protein expression was calculated as the rIOD of protein in the therapeutic groups at each time point divided by the rIOD of the corresponding control group.
RT-qPCR analysis. Total RNA was isolated from tumor tissues frozen at -80˚C using TRIzol reagent according to the manufacturer's instructions (Invitrogen; Thermo Fisher Scientific, Inc.). Containing DNA was removed by RNasefree DNase (Qiagen, Hilden, Germany). mRNA solution (4 µl) was reverse-transcribed with 2.5 µM of random 9-mer primer and RNA PCR kit (AMV; Takara Bio, Inc., Otsu, Japan) following the manufacturer's instruction. PCR amplification was performed for plain SYBR Green I detection in using Light Cycler system (Roche Diagnostic GmbH, Mannheim, Germany) with the following primers specific for MMP-2: 5'-CTGGAATGCCATCCCTGATAA-3' (forward) and 5'-CAAACTTCACGCTCTTGAGACTTT-3' (reverse). Each reaction was conducted in a total volume of 20 µl in glass capillary containing 1 µl of cDNA, 4 mM MgCl, 10% LightCycler-DNA Master SYBR Green I buffer and 0.5 µM of each primer. Thermal cycling condition was as follows: 45 cycles at 95˚C for 30 sec and 60˚C for 30 sec. The expression of all genes was normalized against β-actin. Amplification was analyzed using the 2 -ΔΔCt method (18) . Each experiment both for tissue samples and cells were assayed in triplicate and the final results were determined after three independent experiments.
Statistical analysis. SPSS 19.0 statistical software (IBM SPSS, Inc., Armonk, NY, USA) was used for statistical analyses in the present study. Protein expression, mRNA duplication and tumor necrosis findings among the groups were subjected to Kruskal-Wallis testing. Comparisons between the therapeutic and control groups were performed by Wilcoxon testing. Correlations between the expression of P53 and other proteins or tumor necrosis were evaluated by calculating the Spearman's correlation coefficient. P<0.05 was considered to indicate a statistically significant difference.
Results

Effects of rAd/p53 on tumor volume.
Comparison of the effects on tumor volume between each therapeutic group and their corresponding control group was performed by Wilcoxon test and the results were shown in Fig. 1 . There was no significant difference of the tumor volume between each therapeutic group and their corresponding control group at each time point (P>0.05). In addition, no significant difference in tumor volume was observed among the rAd/p53, rAd/p53 + 5-Fu and 5-Fu groups at each time point (Kruskal-Wallis test; P>0.05). It seemed that all drugs applied included rAd/p53, rAd/p53 + 5-Fu and 5-Fu showed no obvious effects on tumor volume compared to their corresponding control, which was hypothesized to be caused by the relatively short observation time.
Effects of rAd/p53 on tumor necrosis. Tumor necrosis was evaluated by the ratio of the necrotic area on each HE-stained section. As presented in Fig. 2 , the Wilcoxon test demonstrated significant differences in TNR between each therapeutic group and their corresponding groups at different time points.
Following injection of rAd/p53, TNR increased significantly in the therapeutic group at 72, 120 and 168 h compared with that of the control group (Fig. 2A) . Respective W-and P-values were 15.000, 0.043; 15.000, 0.043 and 15.000 and 0.042. In the therapeutic group injected with rAd/P53 + 5-Fu, TNR also increased significantly at 72, 120 and 168 h compared with that of its control group (Fig. 2B) . Respective W-and P-values were 15.000, 0.043; 15.000, 0.043 and 15.000 and 0.043, respectively. Following injection of 5-Fu, the TNR of the therapeutic group increased significantly at 48, 72, 120 and 168 h compared with that of the control group (Fig. 2C) . The W-and P-values at 48, 72, 120 and 168 h were 15.000, 0.043; 15.000, 0.043; 15.000, 0.043, and 15.000 and 0.042, respectively.
Comparison among the three therapeutic groups demonstrated that there was no significant difference in rTNR at each time point after statistical analysis by Kruskal-Wallis (P>0.05; Fig. 2D ). Our results indicated that all three treatments could increase tumor necrosis.
Effects of rAd/p53 on p53, Smad 4 and Brcal expression.
The expression levels of p53, Smad 4 and Brcal following the different treatments were detected by western blot analysis. Quantitative analysis of the results are shown in Figs. 3-5 , and the western blot images of p53, Smad4 and Brcal protein expression are presented in Fig. 6 .
Expression levels of p53 in the rAd/p53 group increased significantly at the time point of 120 and 168 h when compared with that of the control group (P<0.05; Fig. 3A) . A significant increase in the expression of p53 was also observed in the rAd/p53 + 5-Fu group at the time point of 72, 120 and 168 h, when compared with its corresponding control group (P<0.05; Fig. 3B ). However, there was no significant difference in p53 expression levels between the 5-Fu group and its corresponding control group (P>0.05; Fig. 3C ). p53 expression was compared among the three therapeutic groups by Kruskal-Wallis test and the results were shown in Fig. 3D . The highest expression of p53 occurred in the rAd/P53 + 5-Fu group, which was higher than that of the rAd/p53 and 5-Fu groups at 120 and 168 h, respectively (120 h: χ 2 , 4.811; P-values, 6.818 and 0.009; 168 h: χ 2 , 4.811; P-values, 0.028, 6.818 and 0.009). Moreover the expression of p53 was also significantly higher in the rAd/p53 group, compared with the 5-Fu group at 120 and 168 h (χ 2 6.818 and P=0.009 at 120 and 168 h).
Expression of Smad4 increased significantly in the rAd/P53 group at 72, 120 and 168 h when compared with that of the control group (P<0.05; Fig. 4A) . A significant increase in Smad4 expression was also observed in the rAd/p53 + 5-Fu group at 120 and 168 h when compared with its corresponding control group (P<0.05; Fig. 4B ). No significant changes in Smad4 expression were observed in the 5-Fu group compared with its control group at any of the time points (P>0.05; 4C ). Kruskal-Wallis testing (Fig. 4D ) demonstrated that the expression of Smad4 in the rAd/p53 and rAd/p53 + 5-Fu groups were significantly higher than that of the 5-Fu group at 120 h (both χ 2 6.818 and P=0.009). At 168 h, there was no significant difference in Smad4 expression between the rAd/p53 and 5-Fu groups, although both of these groups exhibited expression levels lower than that of the rAd/p53 + 5-Fu group (χ 2 , 9.380 and 10.50; P=0.009 and 0.005, respectively). Changes in the expression levels of Brcal after the various treatments are presented in Fig. 5 . Brcal expression in the rAd/p53 group increased significantly at 72 and 120 h compared with its control group (P<0.05; Fig. 5A ). A significant increase in Brcal expression was observed in the rAd/p53 + 5-Fu and 5-Fu groups at 24 and 48 h (P<0.05), whereas Brcal expression decreased in both groups after 48 h. No significant differences in Brca1 expression were observed between the rAd/p53 + 5-Fu or 5-Fu groups and their corresponding groups at 72, 120 and 168 h (Fig. 5B and C) . The mean IOD ratio of each therapeutic group was analyzed by the Kruskal-Wallis test and the results are shown in Fig. 5D . Brca1 expression in the rAd/p53 group was significantly lower than that of the rAd/p53 + 5-Fu and 5-Fu groups at 24 and 48 h (all χ 2 , 6.818 and P=0.009). However, at 72 and 120 h, Brca1 expression levels in the rAd/p53 and rAd/p53 + 5-Fu groups were higher than that of the 5-Fu group (χ 2 , 10.220 and 11.580; P-values, 0.006, 9.500 and 0.009, and 0.003, 11.180 and 0.004, respectively). These results indicated that rAd/p53 promoted Effects of rAd/p53 on MMP-2 expression. Expression levels of MMP-2 after the different treatments were detected by RT-qPCR and the results are shown in Fig. 7 . Following injection of 5-Fu, there was no significant difference in MMP-2 mRNA copies between the experimental group and its corresponding control group at each time point. However, MMP-2 mRNA copies significantly decreased in the rAd/p53 and rAd/p53 + 5-Fu groups when compared with their corresponding control group from 72 h (P<0.05). In addition, the expression levels of MMP-2 in the rAd/p53 and rAd/p53 + 5-Fu groups were significantly lower than that of the 5-Fu group from 72 h (P<0.05). No significant difference in MMP-2 expression was detected between the rAd/p53 and rAd/p53 + 5-Fu groups at any of the time points (P>0.05). Based on these results, we found that rAd/p53 was capable of inhibiting the expression of tumor invasion and metastasis gene MMP-2.
Spearman's correlation analysis. A positive correlation was detected between the rIOD of p53 expression and the TNR (correlation coefficient, 0.574; P= 0.025). p53 expression also exhibited a positive correlation with the expression of Smad4 (correlation coefficient, 0.905; P<0.001). However, the rIOD of p53 expression showed no correlation with the rIOD of Brca1 expression (correlation coefficient, -0.309; P=0.263). Finally, the expression of p53 had a negative correlation with MMP-2 mRNA expression levels (correlation coefficient, -0.598; P=0.019). These results indicated that p53 expression is positively associated with tumor necrosis, Smad 4 expression and negatively associated with MMP-2 expression.
Discussion
Benefitting from advances of molecular genetics, targeted genes can now be successfully transferred into tumor cells. Since the p53 gene exhibits a strong suppressing effect on human malignant tumor growth, it is one of the most promising targets for gene targeted therapy (19) (20) (21) . Previous studies have demonstrated that p53 gene therapy has an anticancer effect on various solid tumors in vivo and in vitro (12, (22) (23) (24) . Recombinant human Ad/p53 was approved by the State Food and Drug Administration of China in 2003 for the treatment of head and neck squamous cell carcinoma (8) . However, the anti-tumor effects of recombinant human Ad/p53 on cSCC had yet to be explored. In the present study, it was demonstrated that rAd/p53 was able to promote tumor necrosis alone or in combination with 5-Fu. In addition, rAd/p53 upregulated the expression of potent tumor suppressors Smad4 and Brca1, and downregulated the expression of the tumor invasion and metastasis-associated gene, MMP-2. However, rAd/p53 was not demonstrated to have a significant antitumor effect on tumor volume. 
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Volumetric changes in tumor growth kinetics are one of the most direct effects of therapeutic benefit of several antitumor drugs and volumetric measurements during antitumor experiments are also considered standard procedures for in vivo drug validation. In the present study, the anti-tumor effects of rAd/p53 on tumor volume were assessed; however, there were no significant changes in tumor volume between each therapeutic group and their corresponding control groups. In addition, no significant changes in tumor volume were observed among of the three therapeutic groups. These results may be due to the short observation time of seven days. Obvious changes in tumor volume between rAd/p53 and the corresponding control have previously been demonstrated to occur >2 weeks after treatment (12, 22) .
Consistent with previous findings in animal carcinoma models (18, 23, 24) , the expression of exogenous wt-p53 exhibited a positive correlation with tumor necrosis. Similar results of the antitumor effects of rAd/p53 on tumor necrosis were observed. rAd/p53 was able to promote tumor necrosis alone or in combination with 5-Fu. Furthermore, the expression of p53 was demonstrated to be associated with cSCC tumor necrosis in the present study. Despite the lack of significant changes in tumor volume after treatment, rAd/p53 showed a positively suppressive effect on cSCC through the induction of tumor necrosis.
The effects of rAd/p53 on the expression of tumor-associated molecules in cSCC were also investigated in order to elucidate the antitumor mechanism of rAd/p53 in cSCC. The tumor suppressor, Smad4, which has been demonstrated to function constitutively in the transforming growth factor-β signaling pathway, is often mutated or deleted in various malignant neoplasms, including prostate, pancreatic and colorectal cancer (25) . A previous study has demonstrated that conditional knockout of Smad4 was associated with hair follicle defects and cSCC formation in mice (26) . In addition, our previous study identified the downregulation of Smad4 in a human cSCC (A431) cell line (14) . In the present study, wt-p53 was able to increase the expression of Smad4, and p53 expression and Smad4 expression exhibited a close positive correlation after agent administration. As described previously, wt-p53 and Smads physically interact and coordinately induce the expression of numerous tumor suppressor factors, such as sharp-1 and cyclin (27) . The present findings demonstrated that exogenous p53 was able to promote the expression and function of the potent antitumor Smad4 gene, and 5-Fu was demonstrated to prolonged these effects when used in combination.
Brca1, which is a breast cancer susceptibility gene and a potent tumor suppressor, has been reported to have a role in various critical biological processes, including cell differentiation, apoptosis and DNA recombination (27) . Mutation or aberrant expression of Brca1 has been identified in various types of squamous cell carcinoma (28, 29) , and Brca1 is considered to be one of the biomarkers for treatment failure in advanced squamous cervical cancer (15) . Due to its prominent role in squamous cell carcinoma, changes in the expression of Brca1 following rAd/p53 or control treatment were investigated in the present study. The results demonstrated that rAd/p53 treatment alone was able to increase the expression of Brcal, and no synergistic effects on Brcal expression were detected between rAd/p53 and 5-Fu.
MMP-2, which is a zinc-dependent proteinase, is associated with the progression, invasion and metastasis of squamous cell carcinoma, and is a potential prognostic indicator of this type of cancer (30, 31) . In the present study, rAd/p53 treatment exhibited a strong inhibitory effect on MMP-2 expression levels and the expression of these two genes demonstrated a negative correlation. Therefore, these findings suggest that the antitumor effect of p53 may function via the downregulation of MMP-2 in cSCC.
Several limitations of the present study should be noted. Firstly, observation time of seven days to determine the antitumor effects of rAd/p53 on tumor volume was too short to examine obvious changes between the therapeutic and control groups. Secondly, a recombinant adenovirus control was not used in the present study due to lack of resources. Thirdly, the present study was conducted in an animal model of cSCC, which did not allow for the clinical identification of the antitumor effects of exogenous p53 in cSCC; therefore, further study is required.
In conclusion, the present findings suggested that rAd/p53 treatment may promote tumor necrosis alone or in combination with 5-Fu, and the expression of p53 was demonstrated to be associated with tumor necrosis in cSCC. In addition, rAd/p53 administration increased the expression of various potent suppressive genes, including Smad4 and Brca1, and inhibited the expression of the tumor invasion and metastasis-associated gene, MMP-2. These results demonstrated the potent anti-tumor effects of rAd/p53 gene therapy in cSCC. Further study is required for the clinical identification of the antitumor effects of rAd/p53 therapy in cSCC.
